BioNxt Solutions Gains European Patent Milestone for Innovative Drug Delivery
12.11.2025 - 05:15:04 | boerse-global.de
The Canadian biotechnology firm BioNxt Solutions has reached a significant corporate milestone, receiving positive notifications from two major patent authorities. The European Patent Office and the Eurasian Patent Organization have both indicated their readiness to grant a key patent for the company’s sublingual thin-film drug delivery technology, potentially unlocking access to a multi-billion dollar market.
This patent advancement secures potential intellectual property protection across up to 54 legal jurisdictions, representing a market encompassing nearly one billion people. The protected technology involves a sublingual thin film that delivers the active pharmaceutical ingredient Cladribin directly into the bloodstream through the oral mucosa. This administration method requires no swallowing or water, and preliminary Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen - Dreimal die Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
